Xencor Inc (FRA:XE9)
€ 23.4 0.4 (1.74%) Market Cap: 1.63 Bil Enterprise Value: 1.19 Bil PE Ratio: 0 PB Ratio: 2.35 GF Score: 59/100

Xencor Inc At The American Society Of Hematology (ASH) Annual Meeting Transcript

Dec 10, 2019 / 01:30AM GMT
Release Date Price: €37 (-1.07%)
Unidentified Speaker Xencor
Inc. - Company Representative

(inaudible) Dr. Krish Patel, Director of the Lymphoma Program (inaudible) and Investigator for the ongoing baseline study will join us for (inaudible) which will be available for download on the Events and Presentation page of xencor.com.

First, so company management may make forward-looking statements during the presentation, which are subject to risk and uncertainties (inaudible) future results (inaudible) from what expressed or implied by these forward-looking statements. Xencor is (inaudible) obligation or undertaking (inaudible) update or revise these forward-looking statements.

You are encouraged to review risk factors (inaudible). Now, Dr. Bassil Dahiyat, President and Chief Executive Officer of Xencor will introduce the company (inaudible) the presentation (inaudible).

Bassil Dahiyat
Xencor, Inc. - President & CEO

Do you hear me? That's me. So welcome everybody who's joining this evening. Thanks for coming (inaudible) very (inaudible). Welcome to everybody who's logged

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot